Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals
Författare
Summary, in English
Kaposi sarcoma-associated herpesvirus (KSHV) is the most important etiopathological factor of Kaposi's sarcoma (KS) and some specific types of malignant lymphomas. One of the viral lytic genes encodes the KSHV complement control protein (KCP), which functionally mimics human complement inhibitors. Although this protein provides an advantage for evading the complement attack, it can serve as target for adaptive immune response. Herein, we identified anti-KCP IgG antibodies in patients with KS and KSHV-related lymphomas. KCP-specific antibodies were only detected in sera of those patients who had high titres of antibodies against lytic or latent KSHV antigens. Complement control protein domain 2 (CCP2) was found to be the most immunogenic part of the KCP protein. Furthermore, pre-incubation of KCP-expressing CHO cells with patient sera containing anti-KCP antibodies resulted in an increased complement deposition when incubated with human serum.
Publiceringsår
2007
Språk
Engelska
Sidor
8102-8109
Publikation/Tidskrift/Serie
Vaccine
Volym
25
Issue
48
Dokumenttyp
Artikel i tidskrift
Förlag
Elsevier
Ämne
- Medicinal Chemistry
- Microbiology in the medical area
- Other Basic Medicine
Nyckelord
- Complement
- Kaposi sarcoma
- HIV
- Lymphoma
- Antibodies
Status
Published
Forskningsgrupp
- Clinical Chemistry, Malmö
- Protein Chemistry, Malmö
- Clinical Microbiology, Malmö
ISBN/ISSN/Övrigt
- ISSN: 1873-2518